作者: Guillaume Schurtz , Nicolas Lamblin , Christophe Bauters , Patrick Goldstein , Gilles Lemesle
DOI: 10.1016/J.ACVD.2015.04.002
关键词:
摘要: Over the past two decades, use of multiple biomarkers has changed cardiovascular disease management. Recently, several trials have assessed diagnostic and prognostic performances copeptin, especially in patients with heart failure or acute coronary syndromes. Primary results are interesting, copeptin looking promising for: management who present at emergency departments early after chest pain onset risk stratification failure. The purpose this article is to review data on place